Deutsche Bank Downgrades Medco Health Solutions (MHS) to 'Hold' Given Uncertainty Post CalPERS
Get Alerts MHS Hot Sheet
Price: $70.30 --0%
Rating Summary:
5 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
5 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Deutsche Bank downgraded Medco Health Solutions (NYSE: MHS) from Buy to Hold. PT slashed from $77 to $55.
Deutsche analyst says, "Late Last Wednesday, CalPERS, the largest pension fund manager in the US announced that it was terminating its negotiations with MHS following a review of business practices by former employees. In an 8K filed last Friday, MHS stated that it was cooperating with the SEC, and that its Board had deemed an internal investigation as unnecessary. Potential reputational damage to MHS, both from a client as well as investor perspective makes the situation hard to analyze."
For more ratings news on Medco Health Solutions click here and for the rating history of Medco Health Solutions click here.
Shares of Medco Health Solutions closed at $53.19 yesterday.
Deutsche analyst says, "Late Last Wednesday, CalPERS, the largest pension fund manager in the US announced that it was terminating its negotiations with MHS following a review of business practices by former employees. In an 8K filed last Friday, MHS stated that it was cooperating with the SEC, and that its Board had deemed an internal investigation as unnecessary. Potential reputational damage to MHS, both from a client as well as investor perspective makes the situation hard to analyze."
For more ratings news on Medco Health Solutions click here and for the rating history of Medco Health Solutions click here.
Shares of Medco Health Solutions closed at $53.19 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mesoblast completes patient treatment in phase 3 back pain trial
- CleanCore Solutions to rename itself Zone Frontier Inc. on Aug. 31
- Daré Bioscience prices $6M direct offering at $1.37 per share
Create E-mail Alert Related Categories
DowngradesRelated Entities
Deutsche Bank, CalPERSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share